PALO ALTO, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) ("Ocera" or "the Company") today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
Stifel and Cowen and Company are acting as joint bookrunning managers for the offering. JMP Securities is acting as lead manager.
Ocera intends to use the net proceeds from the proposed offering to continue to progress the clinical development of OCR-002 and for working capital and other general corporate purposes.The securities described are being offered by Ocera pursuant to an effective shelf registration statement on Form S-3 including a base prospectus. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement related to the offering will be filed with the Securities and Exchange Commission ("SEC") and will be available on the SEC's website located at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500, or from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, or by calling (631) 274-2806, or by faxing (631) 254-7140. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Ocera Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration, or FDA, for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute on chronic liver disease.